Percentage of HIV-positive pregnant IDU women who received OST during pregnancy

Export Indicator

Percentage of HIV-positive pregnant IDU women who received OST during pregnancy
What it measures

This indicator measures proportion of HIV-positive pregnant drug dependent women who were receiving OST (methadone, buprenorphin) during pregnancy.

Rationale

HIV positive pregnant women who are injecting drugs remain the hardest to reach population by PMTCT interventions. Opioid substitution therapy (OST) is a critical intervention to improve access of IDU women to PMTCT
services.

Numerator

Number of HIV-positive pregnant IDU women who received OST during pregnancy.

Denominator

Number of diagnosed HIV-positive IDU women who had pregnancy registered during the reporting year.

Calculation

Numerator / Denominator

Method of measurement

The numerator is calculated from national programme records aggregated from health care facility registers.

Data quality control and notes for the reporting tool:
It is important to put a note clarifying if the numerator and denominator includes delivering IDU women only, or also include those who terminated there pregnancies.

Measurement frequency
Disaggregation
Explanation of the numerator
Explanation of the denominator
Strengths and weaknesses

OST has been documented as an effective intervention to improve pregnancy outcome, including reduced rates of neonatal morbidity and mortality. Due to stigma and discrimination of IDU women, some of them could under report their injecting drug use, which may in turn have an impact on the indicator and overestimate coverage with OST.

Data utilization: This indicator will help to monitor trends and access of IDU pregnant HIV positive women to OST.

Further information